Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + nab-paclitaxel in advanced triple-negative breast cancer with PIK3CA mutation or PTEN loss
CTR20201097Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alpelisib in triple-negative breast cancer (TNBC), sponsored by Novartis. Started Dec 2020; status: completed.
02
Drugs
alpelisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20201097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201097.